* subjects with signs of active sars-cov-2 infection at the screening visit or within 72 hours prior to the screening visit * subjects who have been diagnosed with a breakthrough infection after receiving two doses of a covid-19 vaccine * subjects with epilepsy or a history of febrile seizures * subjects who receive immunosuppressive or cytotoxic medications. * subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. * subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. * subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study. * subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection. * female subjects who are pregnant or breastfeeding or have planned to become pregnant within one month after the study injection. * subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period. * subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion. * subjects who have donated ≥450 ml of blood or blood products within 28 days prior to the screening visit.

* subjects with signs of active sars-cov-2 infection at the screening visit or within 72 hours prior to the screening visit * subjects who have been diagnosed with a breakthrough infection after receiving two doses of a covid-19 vaccine * subjects with epilepsy or a history of febrile seizures * subjects who receive immunosuppressive or cytotoxic medications. * subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. * subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. * subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study. * subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection. * female subjects who are pregnant or breastfeeding or have planned to become pregnant within one month after the study injection. * subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period. * subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion. * subjects who have donated ≥450 ml of blood or blood products within 28 days prior to the screening visit.

subjects with signs of active sars-cov-2 infection at the screening visit or within 72 hours prior to the screening visit subjects who have been diagnosed with a breakthrough infection after receiving two doses of a covid-19 vaccine subjects with epilepsy or a history of febrile seizures subjects who receive immunosuppressive or cytotoxic medications. subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study. subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection. female subjects who are pregnant or breastfeeding or have planned to become pregnant within one month after the study injection. subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period. subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion. subjects who have donated ≥450 ml of blood or blood products within 28 days prior to the screening visit.

subjects with signs of active sars-cov-2 infection at the screening visit or within 72 hours prior to the screening visit subjects who have been diagnosed with a breakthrough infection after receiving two doses of a covid-19 vaccine subjects with epilepsy or a history of febrile seizures subjects who receive immunosuppressive or cytotoxic medications. subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study. subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection. female subjects who are pregnant or breastfeeding or have planned to become pregnant within one month after the study injection. subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period. subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion. subjects who have donated ≥450 ml of blood or blood products within 28 days prior to the screening visit.